The FTC and Illumina’s Grail: The Tipline for 23 August 2021
Antitrust is not usually a matter of life and death, but administrative law judge D Michael Chappell is going to hear otherwise this week. Starting today, Federal Trade Commission staff will square off with Illumina over the DNA-sequencing company’s completed acquisition of Grail, which is developing an innovative cancer-screening test. Both the government and the merging parties are expected to argue that their opponent is trying to obstruct this life-saving technology.
Subscribe to Global Competition Review
Subscribe and start reading now
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10